BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of its common shares at a price per share of $8.90.

波士顿和蒙特利尔--（商业新闻短讯）--enGene Holdings Inc.（纳斯达克：ENGN或“enGene”或“公司”）是一家临床阶段的遗传药物公司，其非病毒性先导研究产品detalimogene voraplasmid（也称为detalimogene，以前称为EG-70）正在进行一项针对高危卡介苗（BCG）-无反应，非肌肉浸润性膀胱癌（NMIBC）原位癌（Cis）患者的关键研究，今天宣布，已同意以每股8.90美元的价格出售6758311股普通股。

The financing is expected to close on October 29, 2024, subject to customary closing conditions. enGene anticipates the gross proceeds from the private placement to be approximately $60 million, before deducting any offering-related expenses..

根据惯例的交割条件，预计融资将于2024年10月29日结束。enGene预计，在扣除任何与发行相关的费用之前，私募的总收益约为6000万美元。

The financing included participation from new and existing investors, including Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital and Venrock Healthcare Capital Partners.

融资包括新投资者和现有投资者的参与，包括Deep Track Capital、Cormorant Asset Management、Forbion、OrbiMed、Sphera Healthcare、Vestal Point Capital和Venrock Healthcare Capital Partners。

enGene intends to use the net proceeds from this financing to fund the continued development of detalimogene, pre-commercial activities, the potential expansion of the DDX platform, and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and cash equivalents, are expected to be sufficient to fund the current operating plan into 2027..

enGene打算将此次融资的净收益用于资助脱氮剂的持续开发、商业前期活动、DDX平台的潜在扩展以及营运资金和一般公司用途。此次融资的收益加上当前现金和现金等价物，预计足以为2027年的当前运营计划提供资金。

Leerink Partners, Piper Sandler & Co., Guggenheim Securities and Wells Fargo Securities are acting as placement agents to the Company in connection with the private placement.

Leerink Partners、Piper Sandler&Co.、古根海姆证券（Guggenheim Securities）和富国证券（Wells Fargo Securities）担任该公司与私募相关的配售代理。

The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

上述证券尚未根据经修订的《1933年证券法》进行登记。因此，除非根据有效的登记声明或《证券法》登记要求的适用豁免，否则不得在美国发售或出售这些证券。

enGene has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the common shares issued in this private placement. Any offering of the securities under the resale registration statement will only be made by means of a prospectus..

enGene已同意向美国证券交易委员会（“SEC”）提交登记声明，登记本次私募发行的普通股的转售情况。转售登记声明项下的任何证券发行只能通过招股说明书的方式进行。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction..

本新闻稿不构成出售要约或招揽购买要约，也不构成在根据任何该等司法管辖区的证券法进行登记或取得资格之前，在任何司法管辖区内出售该等证券将是非法的。

About enGene

关于enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden.

enGene是一家临床阶段的生物技术公司，通过向粘膜组织和其他器官提供治疗药物，将遗传药物纳入主流，目标是创造新的方法来解决临床需求高的疾病。enGene的主要项目是非肌层浸润性膀胱癌（NMIBC）患者的去消化素-voraplasmid（也称为去消化素，以前称为EG-70），这是一种临床负担很重的疾病。

Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette Guérin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA..

正在进行的多队列LEGEND 2期研究正在评估脱氮菌素，该研究包括一个关键队列，研究卡介苗（BCG）无反应的原位癌（Cis）患者中的脱氮菌素。Detalimogene是使用enGene专有的双衍生低聚壳聚糖（DDX）平台开发的，该平台可以穿透粘膜组织并输送各种大小和类型的货物，包括DNA和各种形式的RNA。

Forward-Looking Statements

前瞻性声明

Some of the statements contained in this press release may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”).

本新闻稿中的一些声明可能构成1995年《私人证券诉讼改革法案》安全港条款所指的前瞻性声明，以及加拿大证券法所指的“前瞻性信息”（统称“前瞻性声明”）。

enGene’s forward-looking statements include, but are not limited to, statements regarding enGene’s expectations, hopes, beliefs, intentions, goals, strategies, forecasts and projections. The words “anticipate”, “appear”, “approximate”, “believe”, “continue”, “could”, “estimate”, “expect”, “foresee”, “intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “seek”, “should”, “would”, and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

enGene的前瞻性陈述包括但不限于关于enGene的期望、希望、信念、意图、目标、策略、预测和预测的陈述。“预期”，“出现”，“近似”，“相信”，“继续”，“可能”，“估计”，“期望”，“预见”，“打算”，“可能”，“可能”，“计划”，“可能”，“潜在”，“预测”，“项目”，“寻求”，“应该”，“将会”以及类似的表达可能会识别前瞻性陈述，但没有这些词语并不意味着陈述不是前瞻性的。

Forward-looking statements may include, for example, statements about: the timing and expectation of the closing of the private placement; the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the period over which enGene estimates the proceeds from the private placement, combined with its existing cash and cash equivalents, will be sufficient to fund its current operating plan..

前瞻性陈述可能包括，例如，关于以下方面的陈述：私募结束的时间和预期；满足与私募相关的惯例交割条件以及由此产生的收益的预期用途；enGene估计私募收益的期间，加上其现有的现金和现金等价物，将足以为其当前的运营计划提供资金。

Many factors, risks, uncertainties and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, that preliminary clinical data may not accurately reflect the complete results of a particular study and remain subject to audit and verification, and final data may differ materially from preliminary data; the Company’s ability to recruit and retain qualified scientific and management personnel; establish clinical trial sites and enroll patients in its clinical trials; execute on the Company’s clinical development plans and ability to secure regulatory approval on anticipated timelines; and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S.

许多因素、风险、不确定性和假设可能导致公司的实际结果、业绩或成就与前瞻性声明明示或暗示的结果、业绩或成就存在重大差异，包括但不限于初步临床数据可能无法准确反映特定研究的完整结果，并仍需接受审计和验证，最终数据可能与初步数据存在重大差异；公司招聘和留住合格科学和管理人员的能力；建立临床试验地点并招募患者进行临床试验；执行公司的临床开发计划，并有能力在预期的时间表上获得监管部门的批准；以及向加拿大证券监管机构提交的关于SEDAR+和美国的文件中详述的其他风险和不确定性。

Securities and Exchange Commission (“SEC”) on EDGAR, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2023 and most recent Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2024 (copies of which may be obtained at www.sedarplus.ca or www.sec.gov)..

美国证券交易委员会（“SEC”）关于EDGAR的报告，包括公司截至2023年10月31日财年的10-K表年度报告中“风险因素”部分所述的内容，以及截至2024年7月31日财年的10-Q表最新季度报告（可在www.sedarplus.ca或www.SEC.gov上获得副本）。

You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene’s assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law.

您不应过度依赖任何前瞻性声明，因为这些声明仅在做出之日起生效。enGene预计随后的事件和发展将导致enGene的评估发生变化。虽然enGene可能会选择在未来的某个时候更新这些前瞻性声明，但enGene明确否认有任何义务这样做，除非适用法律要求。

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved..

本新闻稿中的任何内容均不应被视为任何人表示将实现本文所述的前瞻性声明，或将实现此类前瞻性声明的任何预期结果。